Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Status:	Archived
Conditions:	Alzheimer Disease
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	June 2009
End Date:	December 2013

A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease

This study will evaluate the safety and tolerability of bapineuzumab when administered by
subcutaneous injection. The study is open only to subjects who participated in the preceding
double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab
for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will
receive active treatment (bapineuzumab) and no subjects will receive placebo.

We found this trial at

sites

Pfizer Investigational Site

Atlanta, Georgia 30309

from

Atlanta, GA